DISINTEGRIN VARIANTS AND PHARMACEUTICAL USES THEREOF

Woei-Jer Chuang (Inventor)

Research output: Patent

Abstract

The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective .alpha.v.beta.3 integrin antagonists for treatment and prevention of .alpha.v.beta.3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant .sup.48ARLDDL.sup.53. The invention also relates to the use of the polypeptides of the invention for the treatment and prevention of .alpha.v.beta.3 integrin-associated diseases.
Original languageEnglish
Patent number8183201
Publication statusPublished - 1800

Fingerprint

Disintegrins
Integrins
Pharmaceutical Preparations
Proteins
Peptides

Cite this

@misc{8057b01f070c4474a0f094fdb32608bd,
title = "DISINTEGRIN VARIANTS AND PHARMACEUTICAL USES THEREOF",
abstract = "The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective .alpha.v.beta.3 integrin antagonists for treatment and prevention of .alpha.v.beta.3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant .sup.48ARLDDL.sup.53. The invention also relates to the use of the polypeptides of the invention for the treatment and prevention of .alpha.v.beta.3 integrin-associated diseases.",
author = "Woei-Jer Chuang",
year = "1800",
language = "English",
type = "Patent",
note = "8183201",

}

TY - PAT

T1 - DISINTEGRIN VARIANTS AND PHARMACEUTICAL USES THEREOF

AU - Chuang, Woei-Jer

PY - 1800

Y1 - 1800

N2 - The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective .alpha.v.beta.3 integrin antagonists for treatment and prevention of .alpha.v.beta.3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant .sup.48ARLDDL.sup.53. The invention also relates to the use of the polypeptides of the invention for the treatment and prevention of .alpha.v.beta.3 integrin-associated diseases.

AB - The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective .alpha.v.beta.3 integrin antagonists for treatment and prevention of .alpha.v.beta.3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant .sup.48ARLDDL.sup.53. The invention also relates to the use of the polypeptides of the invention for the treatment and prevention of .alpha.v.beta.3 integrin-associated diseases.

M3 - Patent

M1 - 8183201

ER -